Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.

BACKGROUND: Hepatocellular carcinoma (HCC) treatment remains a big challenge in the field of oncology. The liver disease (viral or not viral) underlying HCC turned out to be crucial in determining the biologic behavior of the tumor, including its response to treatment. The aim of this analysis was to investigate the role of the etiology of the underlying liver disease in survival outcomes. PATIENTS AND METHODS: We conducted a multicenter retrospective study on a large cohort of patients treated with lenvatinib as first-line therapy for advanced HCC from both Eastern and Western institutions. Univariate and multivariate analyses were performed. RESULTS: Among the 1232 lenvatinib-treated HCC patients, 453 (36.8%) were hepatitis C virus positive, 268 hepatitis B virus positive (21.8%), 236 nonalcoholic steatohepatitis (NASH) correlate (19.2%) and 275 had other etiologies (22.3%). The median progression-free survival (mPFS) was 6.2 months [95% confidence interval (CI) 5.9-6.7 months] and the median overall survival (mOS) was 15.8 months (95% CI 14.9-17.2 months). In the univariate analysis for OS NASH-HCC was associated with longer mOS [22.2 versus 15.1 months; hazard ratio (HR) 0.69; 95% CI 0.56-0.85; P = 0.0006]. In the univariate analysis for PFS NASH-HCC was associated with longer mPFS (7.5 versus 6.5 months; HR 0.84; 95% CI 0.71-0.99; P = 0.0436). The multivariate analysis confirmed NASH-HCC (HR 0.64; 95% CI 0.48-0.86; P = 0.0028) as an independent prognostic factor for OS, along with albumin-bilirubin (ALBI) grade, extrahepatic spread, neutrophil-to-lymphocyte ratio, portal vein thrombosis, Eastern Cooperative Oncology Group (ECOG) performance status and alpha-fetoprotein. An interaction test was performed between sorafenib and lenvatinib cohorts and the results highlighted the positive predictive role of NASH in favor of the lenvatinib arm (P = 0.0047). CONCLUSION: NASH has been identified as an independent prognostic factor in a large cohort of patients with advanced HCC treated with lenvatinib, thereby suggesting the role of the etiology in the selection of patients for tyrosine kinase treatment. If validated, this result could provide new insights useful to improve the management of these patients.

Utility of intravoxel incoherent motion MR imaging for distinguishing recurrent metastatic tumor from treatment effect following gamma knife radiosurgery: initial experience.

BACKGROUND AND PURPOSE: Intravoxel incoherent motion MR imaging can simultaneously measure the diffusion and perfusion characteristics of brain tumors. Our aim was to determine the utility of intravoxel incoherent motion-derived perfusion and diffusion parameters for assessing the treatment response of metastatic brain tumor following gamma knife radiosurgery. MATERIALS AND METHODS: Ninety-one consecutive patients with metastatic brain tumor treated with gamma knife radiosurgery were assessed by using intravoxel incoherent motion imaging. Two readers independently calculated the 90th percentile and the 10th percentile histogram cutoffs for perfusion, normalized CBV, diffusion, and ADC. Areas under the receiver operating characteristic curve and interreader agreement were assessed. RESULTS: With the combination of the 90th percentile histogram cutoff for perfusion and the 10th percentile histogram cutoff for diffusion, the sensitivity and specificity for differentiating recurrent tumor and treatment were 79.5% and 92.3% for reader 1 and 84.6% and 94.2% for reader 2, respectively. With the combination of the 90th percentile histogram cutoff for normalized CBV and the 10th percentile histogram cutoff for ADC, the sensitivity and specificity for differentiating recurrent tumor and treatment were 69.2% and 100.0% for reader 1 and 74.3% and 100.0% for reader 2, respectively. Compared with the combination of 90th percentile histogram cutoff for normalized CBV and the 10th percentile histogram cutoff for ADC, adding intravoxel incoherent motion to 90th percentile histogram cutoff for normalized CBV substantially improved the diagnostic accuracy for differentiating recurrent tumor and treatment from 86.8% to 92.3% for reader 1 and from 89.0% to 93.4% for reader 2, respectively. The intraclass correlation coefficients between readers were higher for perfusion parameters (intraclass correlation coefficient range, 0.84-0.89) than for diffusion parameters (intraclass correlation coefficient range, 0.68-0.79). CONCLUSIONS: Following gamma knife radiosurgery, intravoxel incoherent motion MR imaging can be used as a noninvasive imaging biomarker for differentiating recurrent tumor from treatment effect in patients with metastatic brain tumor.

Clinical significance of an increased cochlear 3D fluid-attenuated inversion recovery signal intensity on an MR imaging examination in patients with acoustic neuroma.

BACKGROUND AND PURPOSE: The increased cochlear signal on FLAIR images in patients with acoustic neuroma is explained by an increased concentration of protein in the perilymphatic space. However, there is still debate whether there is a correlation between the increased cochlear FLAIR signal and the degree of hearing disturbance in patients with acoustic neuroma. Our aim was to investigate the clinical significance of an increased cochlear 3D FLAIR signal in patients with acoustic neuroma according to acoustic neuroma extent in a large patient cohort. MATERIALS AND METHODS: This retrospective study enrolled 102 patients with acoustic neuroma, who were divided into 2 groups based on tumor location; 22 tumors were confined to the internal auditory canal and 80 extended to the cerebellopontine angle cistern. Pure tone audiometry results and hearing symptoms were obtained from medical records. The relative signal intensity of the entire cochlea to the corresponding brain stem was calculated by placing regions of interest on 3D FLAIR images. Statistical analysis was performed to compare the cochlear relative signal intensity between the internal auditory canal acoustic neuroma and the cerebellopontine angle acoustic neuroma. The correlation between the cochlear relative signal intensity and the presence of hearing symptoms or the pure tone audiometry results was investigated. RESULTS: The internal auditory canal acoustic neuroma cochlea had a significantly lower relative signal intensity than the cerebellopontine angle acoustic neuroma cochlea (0.42±0.15 versus 0.60±0.17, P<.001). The relative signal intensity correlated with the audiometric findings in patients with internal auditory canal acoustic neuroma (r=0.471, P=.027) but not in patients with cerebellopontine angle acoustic neuroma (P=.427). Neither internal auditory canal acoustic neuroma nor cerebellopontine angle acoustic neuroma showed significant relative signal intensity differences, regardless of the presence of hearing symptoms (P>.5). CONCLUSIONS: The cochlear signal on FLAIR images may be an additional parameter to use when monitoring the degree of functional impairment during follow-up of patients with small acoustic neuromas confined to the internal auditory canals.